Integrated Filing — IndAS



General information about company

Scrip Code 543654
NSE Symbol MEDANTA
MSEI Symbol NOTLISTED
ISIN INE474Q01031
Name of company GLOBAL HEALTH LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 14-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 06-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Healthcare services
Start date and time of board meeting 14-05-2026   14:00:00
End date and time of board meeting 14-05-2026   16:10:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 04-02-2025
Indicate Company website link for updated RPT policy of the Company https://www.medanta.org/investor_relations/corporate-governance/governance-codes-policies
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No default on payment of Loans.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 96,062.90 3,70,937.80
Other income 3,580.50 10,640.80
Total income 99,643.40 3,81,578.60
2 Expenses
(a) Cost of materials consumed 18,864.40 78,585.60
(b) Purchases of stock-in-trade (0.50) 194.30
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 461.10
(d) Employee benefit expense 25,568.10 98,925.90
(e) Finance costs 1,346.40 4,108.50
(f) Depreciation, depletion and amortisation expense 5,220.80 17,090.70
(f) Other Expenses
1 Retainers and consultants fee 15,594.00 54,453.20
2 Other expenses 16,702.70 62,831.60
Total other expenses 32,296.70 1,17,284.80
Total expenses 83,295.90 3,16,650.90
3 Total profit before exceptional items and tax 16,347.50 64,927.70
4 Exceptional items 0.00 37.70
5 Total profit before tax 16,347.50 64,965.40
6 Tax expense
7 Current tax 3,184.60 13,124.20
8 Deferred tax 749.80 2,221.10
9 Total tax expenses 3,934.40 15,345.30
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 12,413.10 49,620.10
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 12,413.10 49,620.10
17 Other comprehensive income net of taxes 342.70 333.00
18 Total Comprehensive Income for the period 12,755.80 49,953.10
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 5,373.80 5,373.80
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 3,95,882.80
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.62 18.46
Diluted earnings (loss) per share from continuing operations 4.61 18.42
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.62 18.46
Diluted earnings (loss) per share from continuing and discontinued operations 4.61 18.42
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 2,88,935.80
Capital work-in-progress 11,970.10
Investment property
Goodwill 0.00
Other intangible assets 1,378.50
Intangible assets under development 5.90
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 38,936.80
Trade receivables, non-current
Loans, non-current 14,363.00
Other non-current financial assets
1 Other financial assets 10,479.20
Total of other non-current financial assets 10,479.20
Total non-current financial assets 63,779.00
Deferred tax assets (net) 430.60
Other non-current assets
1 Income-tax assets (net) 3,564.00
2 Other non-current assets 8,048.80
Total of other non-current assets 11,612.80
Total non-current assets 3,78,112.70
2 Current assets
Inventories 5,089.70
Current financial asset
Current investments 0.00
Trade receivables, current 38,685.30
Cash and cash equivalents 9,590.80
Bank balance other than cash and cash equivalents 98,045.00
Loans, current 1,035.50
Other current financial assets
Total of other current financial assets 2,864.80
Total current financial assets 1,50,221.40
Current tax assets (net) 1,723.10
Other current assets
Total of other current assets
Total current assets 1,57,034.20
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 5,35,146.90
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 5,373.80
Other equity 3,95,882.80
Total equity attributable to owners of parent 4,01,256.60
Non controlling interest
Total equity 4,01,256.60
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 65,406.50
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
Total of other non-current financial liabilities
Total non-current financial liabilities 65,406.50
Provisions, non-current 10,854.50
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
1 Other non-current liabilities 4,518.00
Total of other non-current liabilities 4,518.00
Total non-current liabilities 80,779.00
Current liabilities
Current financial liabilities
Borrowings, current 2,859.50
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 7,294.90
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 12,914.10
Total Trade payable 20,209.00
Other current financial liabilities
1 Other financial liabilities 11,985.20
Total of other current financial liabilities 11,985.20
Total current financial liabilities 35,053.70
Other current liabilities 15,150.40
1 Other current liabilities 15,150.40
Total of other current liabilities 15,150.40
Provisions, current 2,907.20
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 53,111.30
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 1,33,890.30
Total equity and liabilites 5,35,146.90
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss (479.40) (466.40)
3 Amount of items that will be reclassified to profit and loss
1 Equity instruments through OCI (16.00) (16.00)
Total Amount of items that will be reclassified to profit and loss (16.00) (16.00)
4 Income tax relating to items that will be reclassified to profit or loss 120.70 117.40
5 Total Other comprehensive income 342.70 333.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 64,965.40
Adjustments for reconcile profit (loss)
Adjustments for finance costs 4,108.50
Adjustments for decrease (increase) in inventories (190.20)
Adjustments for decrease (increase) in trade receivables, current (10,499.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 0.00
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 3,721.50
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 17,090.70
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 39.60
Adjustments for dividend income 0.00
Adjustments for interest income 9,736.20
Adjustments for share-based payments 3,685.70
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (4,984.10)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 3,236.50
Net cash flows from (used in) operations 68,201.90
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 10,845.70
Other inflows (outflows) of cash (24.50)
Net cash flows from (used in) operating activities 57,331.70
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 2,402.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 29.80
Purchase of property, plant and equipment 67,555.70
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 1,746.20
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 8,932.80
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (33,886.30)
Net cash flows from (used in) investing activities (93,135.20)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 2.10
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 34,521.20
Repayments of borrowings 0.00
Payments of lease liabilities 3,306.10
Dividends paid 1,344.00
Interest paid 2,503.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (982.40)
Net cash flows from (used in) financing activities 26,387.80
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (9,415.70)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (9,415.70)
Cash and cash equivalents cash flow statement at beginning of period 19,006.50
Cash and cash equivalents cash flow statement at end of period 9,590.80





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Walker Chandiok & Co LLP Yes 31-05-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Global Health Limited Devyani International Limited Common director Any other transaction Revenue Share from Food Court & Reimbursement of expenses 0.00 As per approved terms 242.00 46.00 39.40
2 Global Health Limited Devyani International Limited Common director Any other transaction Security deposit received 0.00 As per approved terms 10.00 5.00 15.00
3 Global Health Limited Devyani International Limited Common director Sale of goods or services 100.00 As per approved terms 0.10 5.20 5.20
4 Global Health Limited Global Health Patliputra Private Limited Subsidiary Interest received 0.00 As approved by board 576.40 0.00 0.00
5 Global Health Limited Global Health Patliputra Private Limited Subsidiary Any other transaction Loan Transaction 20,000.00 As per approved terms 413.20 13,932.50 13,519.30
6 Global Health Limited Global Health Patliputra Private Limited Subsidiary Any other transaction Transfer of Gratuity / Leave Encashment due to transfer in of employee 0.00 As per approved terms 0.20 0.00 0.20
7 Global Health Limited Global Health Patliputra Private Limited Subsidiary Any other transaction Transfer of Gratuity / Leave Encashment due to transfer in of employee 0.00 As per approved terms 1.40 0.00 1.40
8 Global Health Limited Global Health Patliputra Private Limited Subsidiary Any other transaction Rendering healthcare services 1,000.00 The transaction limit of INR 100 million is for all types of related party transactions 176.30 28.90 28.70
9 Global Health Limited IFANFLEX Private Limited Entity Control by director Any other transaction Recruitment expenses 0.00 As per approved terms 5.00 6.00 (1.00)
10 Global Health Limited Medanta Foundation – Poor And Needy Patients Welfare Trust KMP of Company are trustee of Trust Any other transaction CSR expenditure 1,250.00 As per approved terms 610.10 0.00 0.00
11 Global Health Limited Medanta Foundation – Poor And Needy Patients Welfare Trust KMP of Company are trustee of Trust Sale of goods or services 100.00 As per approved terms 72.40 7.80 2.80
12 Global Health Limited Medanta Foundation – Poor And Needy Patients Welfare Trust KMP of Company are trustee of Trust Any other transaction Reimbursement of Expenses 0.00 As per approved terms 7.70 0.00 0.00
13 Global Health Limited Medanta Foundation – Poor And Needy Patients Welfare Trust KMP of Company are trustee of Trust Any other transaction Donation 100.00 As per approved terms 67.50 0.00 0.00
14 Global Health Limited RJ Corp Limited Entity Control by director Sale of goods or services 100.00 As per approved terms 0.90 4.70 4.40
15 Global Health Limited S.A.S Infotech Private Limited Entity Control by director Any other transaction Charge Reimbursement of expenses and Rent 0.00 Actual electricity consumed 211.10 144.60 51.00
16 Global Health Limited S.A.S Infotech Private Limited Entity Control by director Any other transaction Rent 0.00 As per approved terms 1.40 1.70 1.60
17 Global Health Limited Suman Sachdeva Entity Control by director Any other transaction Rent 0.00 As per approved terms 0.10 0.00 0.10
18 Global Health Limited SAS Servizio Private Limited Entity Control by director Any other transaction Rental income 0.00 As per approved terms 0.10 0.10 0.20
19 Global Health Limited Varun Beverages Limited Entity Control by director Sale of goods or services 100.00 As per approved terms 0.00 0.00 0.00
20 Global Health Limited Chambers of Shyel Trehan Entity Control by relative of director Any other transaction Legal Services 60.00 As per approved terms 29.40 7.20 4.50
21 Global Health Limited Language Architect Body Entity Control by director Any other transaction Interior design services 0.00 As per approved terms 150.30 8.00 8.00
22 Global Health Limited GHL Pharma Diagnostics Pvt Ltd Subsidiary Any other transaction Loan Transaction 4,500.00 As per approved terms 1,312.50 2,416.70 1,879.20
23 Global Health Limited GHL Pharma Diagnostics Pvt Ltd Subsidiary Any other transaction Transfer of Gratuity / Leave Encashment due to transfer in of employee 0.00 As per approved terms 0.20 0.00 0.20
24 Global Health Limited GHL Pharma Diagnostics Pvt Ltd Subsidiary Any other transaction Transfer of Gratuity / Leave Encashment due to transfer out of employee 0.00 As per approved terms 22.40 0.00 22.40
25 Global Health Limited GHL Pharma Diagnostics Pvt Ltd Subsidiary Interest received 0.00 As per approved terms 90.80 0.00 0.00
26 Global Health Limited GHL Pharma Diagnostics Pvt Ltd Subsidiary Any other transaction Office Space Income 0.00 As per approved terms 17.10 4.90 4.10
27 Global Health Limited GHL Pharma Diagnostics Pvt Ltd Subsidiary Any other transaction Revenue sharing Income 0.00 As per approved terms 1,986.50 1,444.20 1,711.70
28 Global Health Limited GHL Pharma Diagnostics Pvt Ltd Subsidiary Any other transaction Office Space Expense 0.00 As per approved terms 17.00 0.50 10.60
29 Global Health Limited GHL Pharma Diagnostics Pvt Ltd Subsidiary Any other transaction Revenue sharing Expenses 0.00 As per approved terms 95.10 95.80 18.60
30 Global Health Limited GHL Hospital Limited Subsidiary Any other transaction Transfer of Gratuity / Leave Encashment due to transfer out of employee 0.00 As per approved terms 0.40 0.00 0.40
31 Global Health Limited GHL Hospital Limited Subsidiary Any other transaction Investment in Equity 2,125.00 As per approved terms 0.00 285.00 285.00
32 Global Health Limited GHL Hospital Limited Subsidiary Any other transaction Investment in Fully Convertible Debenture 0.00 As per approved terms 2,250.00 0.00 2,250.00
33 Global Health Limited Medanta Institute of Education & Research (Trust) Director is the Trustees of Trust Any other transaction Donation 50.00 As per approved terms 22.50 0.00 0.00
34 Global Health Limited Medanta Institute of Education & Research (Trust) Director is the Trustees of Trust Any other transaction Rental income 0.00 As per approved terms 6.00 21.00 21.00
35 Global Health Limited Praveen Mahajan Director Any other transaction Director's sitting fees 0.00 As per approved terms 11.00 0.00 3.60
36 Global Health Limited Vikram Singh Mehta Director Any other transaction Director's sitting fees 0.00 As per approved terms 11.00 0.00 4.50
37 Global Health Limited Hari Shanker Bhartia Director Any other transaction Director's sitting fees 0.00 As per approved terms 1.00 0.00 0.00
38 Global Health Limited Rajan Bharti Mittal Director Any other transaction Director's sitting fees 0.00 As per approved terms 6.00 0.00 0.90
39 Global Health Limited Ravi Gupta Director Any other transaction Director's sitting fees 0.00 As approved by board 11.00 0.00 2.70
40 Global Health Limited Dr. Naresh Trehan Director Any other transaction Salaries and other benefits 0.00 As per approved terms 1,498.60 0.00 0.00
41 Global Health Limited Pankaj Sahni Director Any other transaction Salaries and other benefits 0.00 As per approved terms 367.60 55.10 110.20
42 Global Health Limited Rahul Ranjan KMP Any other transaction Salaries and other benefits 0.00 As per approved terms 59.20 0.00 0.00
43 Global Health Limited Yogesh Kumar Gupta KMP Any other transaction Salaries and other benefits 0.00 As per approved terms 170.10 19.20 38.40
44 Global Health Limited GHL Pharma Diagnostics Pvt Ltd Subsidiary Any other transaction Amount due to GHLPDPL for CM relief fund patient 0.00 As per approved terms 35.60 115.70 35.60
45 GHL Hospital Limited Anuradha Bhadana KMP Any other transaction Salaries and other benefits 0.00 As approved by board 5.30 0.00 0.00
46 GLOBAL HEALTH PATLIPUTRA PRIVATE LIMITED Devyani International Limited Common director Any other transaction Security deposit received 0.00 As approved by board 0.00 5.00 5.00
47 GLOBAL HEALTH PATLIPUTRA PRIVATE LIMITED Devyani International Limited Common Director Any other transaction Revenue Share from Food Court 0.00 As approved by board 25.30 5.80 5.90
48 GLOBAL HEALTH PATLIPUTRA PRIVATE LIMITED Praveen Mahajan Director Any other transaction Director sitting fees 0.00 As approved by board 0.70 0.00 0.90
49 GHL Pharma Diagnostics Pvt Ltd Mahak KMP Any other transaction Salary 0.00 As approved by board 6.90 0.00 0.00
50 GLOBAL HEALTH PATLIPUTRA PRIVATE LIMITED Dr. Ravi Shankar Singh KMP Any other transaction Salary 0.00 As approved by board 98.30 6.70 13.20
51 GLOBAL HEALTH PATLIPUTRA PRIVATE LIMITED Om Prakash Choubey KMP Any other transaction Salary 0.00 As approved by board 15.10 0.00 0.00
52 GLOBAL HEALTH PATLIPUTRA PRIVATE LIMITED IFANFLEX PRIVTAE LIMITED Entity Control by director Any other transaction Recruitment expenses 0.00 As approved by board 15.40 0.00 0.00
53 GLOBAL HEALTH PATLIPUTRA PRIVATE LIMITED Anurag Gupta KMP Any other transaction Salary 0.00 As approved by board 23.80 0.00 0.00
54 GLOBAL HEALTH PATLIPUTRA PRIVATE LIMITED Medanta Foundation – Poor And Needy Patients Welfare Trust KMP of Company are trustee of Trust Sale of goods or services 100.00 As per approved terms 7.30 4.00 0.00
55 GHL Pharma Diagnostics Pvt Ltd Global Health Patliputra Private Limited Fellow subsidiary Any other transaction Revenue Sharing 0.00 As approved by board 304.00 222.80 254.00
56 GHL Pharma Diagnostics Pvt Ltd Global Health Patliputra Private Limited Fellow subsidiary Any other transaction Rental Expenses 0.00 As approved by board 3.00 0.50 0.50
57 GHL Pharma Diagnostics Pvt Ltd Anup Kumar Jha KMP Any other transaction Salary 0.00 As approved by board 24.10 1.90 4.20
58 GHL Pharma Diagnostics Pvt Ltd Malik Mohd Ashhab KMP Any other transaction Salary 0.00 As approved by board 28.60 0.00 3.40
59 GHL Pharma Diagnostics Pvt Ltd Mr Rajdeep Panwar KMP Any other transaction Salary 0.00 As approved by board 16.70 6.80 0.00
60 Global Health Limited Skipper Healthcare Pvt Ltd Entity Control by relative of director Any other transaction Rent Income 0.00 As approved by board 0.30 0.00 0.00
61 Global Health Limited Praveen Mahajan Director Any other transaction Director Commission 24.00 As per approved terms 11.00 11.00 19.80
62 Global Health Limited Vikram Singh Mehta Director Any other transaction Director Commission 24.00 As per approved terms 11.00 11.00 19.80
63 Global Health Limited Hari Shanker Bhartia Director Any other transaction Director Commission 24.00 As per approved terms 11.00 11.00 19.80
64 Global Health Limited Rajan Bharti Mittal Director Any other transaction Director Commission 24.00 As per approved terms 11.00 11.00 19.80
65 Global Health Limited Ravi Gupta Director Any other transaction Director Commission 24.00 As per approved terms 11.00 11.00 19.80
66 Global Health Limited Cryoviva Lifesciences Private Limited Enterprises over which KMPs have control Sale of goods or services 100.00 As approved by board 3.80 2.80 6.20
67 Global Health Limited Global Health Institute of Medical Sciences Foundation Subsidiary Any other transaction Investment in Equity 0.00 As approved by board 1.00 2.00 3.00
Total value of transaction during the reporting period 11,201.80